Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-12
2011-07-12
Spector, Lorraine (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S134100, C424S139100, C424S133100, C424S141100, C424S146100, C514S017700, C530S387900, C530S388100, C530S388260, C530S391300
Reexamination Certificate
active
07977314
ABSTRACT:
The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1. In addition, the invention includes methods of diagnosing Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis in a subject. Also, the invention provides methods of identifying substances for the treatment or prevention of Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis and kits using the binding proteins of the invention.
REFERENCES:
patent: 4806627 (1989-02-01), Wisniewski et al.
patent: 4910133 (1990-03-01), Uda et al.
patent: 4940659 (1990-07-01), Warrington et al.
patent: 5834457 (1998-11-01), Bredesen et al.
patent: 5849290 (1998-12-01), Brown et al.
patent: 6270954 (2001-08-01), Welch et al.
patent: 6406864 (2002-06-01), Prusiner et al.
patent: 6541195 (2003-04-01), Welch et al.
patent: 6677125 (2004-01-01), Prusiner et al.
patent: 6743771 (2004-06-01), Douglas et al.
patent: 6765088 (2004-07-01), Korth et al.
patent: 7041807 (2006-05-01), Cashman et al.
patent: 7439324 (2008-10-01), Cashman
patent: 2002/0123072 (2002-09-01), Prusiner et al.
patent: 2003/0022243 (2003-01-01), Kondejewski et al.
patent: 2006/0194821 (2006-08-01), Lansbury et al.
patent: 2006/0211079 (2006-09-01), Hazen et al.
patent: 2006/0280733 (2006-12-01), Kayed et al.
patent: 2007/0003977 (2007-01-01), Cashman et al.
patent: 2008/0132685 (2008-06-01), Chakrabartty et al.
patent: 2008/0206251 (2008-08-01), Cashman et al.
patent: 2009/0098151 (2009-04-01), Cashman
patent: 2408762 (2003-04-01), None
patent: 2452946 (2004-06-01), None
patent: 2437675 (2005-02-01), None
patent: 2437999 (2005-02-01), None
patent: 1668369 (2004-08-01), None
patent: 2003-521477 (2000-12-01), None
patent: 2006-523496 (2004-08-01), None
patent: WO 00/12718 (2000-03-01), None
patent: WO00/22438 (2000-04-01), None
patent: WO00/78344 (2000-12-01), None
patent: WO01/06989 (2001-02-01), None
patent: WO 2004/024090 (2004-03-01), None
patent: WO 2005/019828 (2005-03-01), None
patent: WO 2005/077040 (2005-08-01), None
patent: WO 2007/025385 (2007-03-01), None
patent: WO 2007/067900 (2007-06-01), None
patent: WO 2007/098607 (2007-09-01), None
Gruzman et al., PNAS, 104(30):12524-12529, Jul. 16, 2007.
Kabashi et al. Annals of Neurology, 62(6): 553-559, Dec. 2007.
Le Pecheur et al., FEBS Letters, 579(17): 3613-3618, 2005.
Haenggeli et al., Neurobiology of Disease, 26:146-152, 2007.
Pardo, Carlos, et al. “Superoxide, dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons”, Neurobiology, Proc. Natl. Acad. Sci., Feb. 1995, vol. 92, pp. 954-958.
Choi, et al.; Oxidative modifications and Aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. The Journal of Biological Chemistry. Mar. 25, 2005. pp. 11648-11655, vol. 280, No. 12. Published online Jan. 19, 2005.
Kalnine N. et al., UnitProt Accession No. Q6NR8. Superoxide dismutase 1. [online] May 10, 2005.
Gelinas D.S. et al., Immunotherapy for Alzheimer's disease. Proceedings for the National Academy of Sciences of the United States of America. Oct. 5, 2004. vol. 101, suppl. 2, pp. 14657-14662.
Griffin and Cashman, Progress in prion vaccines and immunotherapies. Expert Opinion on Biological Therapies. Jan. 6, 2005. vol. 5, No. 1, pp. 97-100.
Burgess et al., Possible Dissociation of the Herapin-binding and Mitogenic Activities of Heparin-bidning (Acid Fibroplast) Growth-Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, The Journalof. Cell Bioology 1990, 111:2129-2138.
Bowie et al., Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, Science, 1990, 247:1306-1310.
Pawson et al., Assembly of Cell Regulatory Systems Through Protein Interaction Domains, 2003, Science 300:445-452.
Kim et al.; Aggregation of Alfa-Synclucein induced by the Cu,Zn-Superoxide dismutase and hydrogen peroxide system, Free Rad Biol. Med. 2002. 32:544-550.
Product No. S-2147 Product Information Sheet [online] published Aug. 1996.
UniProtKB/Swiss-Prot entry P00441, SODC—HUMAN, Jul. 21, 1986.
Harris et al., Keyhole limpet hemocyanin (KLH): a biomedical review, Micron, Dec. 1999, 30: 597-623.
Johnston et al., Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis, PNAS, Nov. 2000, 97(23): 12571-12576.
Kunst et al., Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel; protein interactions, Nature Genetics, Jan. 1997,15:91-94.
Rakhit R, et al. An Immunological epitope selective for pathological monomer-misfolded SOD1 in ALS, nature medicine Jun. 2007, vol. 13, No. 6, pp. 754-759.
Watanabe et al., Adherent Monomer-Misfolded SOD1, PLos ONE, Oct. 2008; vol. 3, issue 10, e:3497.
Ezzi et al., Wild—type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation, J Neurochem, Jul. 2007; 102, 107-178.
Brettschneider et al., Axonal damage markers in cerebrospinal fluid are increased in ALS, Neurology, 2006, May 2008, 66(6): 852-6.
Urushitani et al., The endoplasmic reticulum-Golgi pathway is a target for translocation and aggregation of mutant superoxide dismutes linked to ASL, The FASEB Journal vol. 22, pp. 2476-2487, Jul. 2008.
Jacobsson et al., Brain, 124:1461, 2001.
Liu H.S. et al., Lack of Evidence of Monomer/Misfolded Superoxide Dismutase-1 in Sporadic Amyotrophic Lateral Sclerosis, Annals of Neurology, vol. 66, No. 1, pp. 75-80, Jul. 2009.
Kerman, A., Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neurophathol, Jan. 2010, 119:335-344.
Dunitz M., Session 7A protein folding and degradation effects: Function of the proteasome in cell regulation and neuromuscular disease, Amytrophic Lateral Sclerosis, 2005, 6: 33-35.
Valentine J.S. et al, Copper-Zinc Superoxide dismutase and amytrophoc lateral sclerosis, Annual Rev. Biochem. 2005, 74: 563-593.
Kabashi et al., Oxidizewd/Misfolded Superoxide Dismutase-1: The Case of All Amyotrophic Lateral Sclerosis?, Annals of Neurologym 62(6): 553-559, Dec. 2007.
Goodall E.F. et al., Amyotrophic later sclerosis (motor neuron disease): proposed mechanism and pathways to treatment, Expert Reviews in Molecular Reviews, 2006, 8(11): 1-24.
Julien, Mouse models of amyotrophic lateral sclerosis, Elsevier Disease Models, 2006, 3(4): 331-339.
Otvos, et al. Curr. Protein Pept. Sci. Dec. 2002; 3: 643-52.
Liu H.S. et al., P139 an immunization strategy for treating amyotrphic lateral sclerosis that targets misfolded SOD1, Amyotrophic Lateral Sclerosis 2007 (Suppl 1); 8:140-155, Abstract p. 150.
Bruijn L. et al, ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containg inclusions, Neuron 1997, vol. 18(2): 327-338.
Kerman A, et al., P163 Investigation of CuZn superoxide dismutase misfolding and aggregation in ALS using conformation-specific antibodies. Amyotrophic Lateral Sclerosis 2007 (Suppl 1); 8:156-177, Abstract p. 164.
Kayed, R. et al.; Common Structure of Soluble Amyloid Oli
Amorfix Life Sciences Limited
Bereskin & Parr LLP
Courage Noel
DeLuca Carmela
MacFarlane Stacey
LandOfFree
Methods and compositions to treat and detect misfolded-SOD1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions to treat and detect misfolded-SOD1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions to treat and detect misfolded-SOD1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684380